Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Trial Profile

Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Eribulin (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2016 Status changed from active, no longer recruiting to discontinued due Slow accrual.
    • 29 Jul 2015 Planned End Date changed from 1 Oct 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 29 Jul 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top